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with suicide genes will need procedures for therapy planning and
monitoring. Finally, new biomolecules will be developed by bioen-
gineering methods which may be used for isotope-based diagno-
sis and treatment of disease.
doi:10.1016/j.ejcsup.2006.04.021
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With an overall 5-year survival rate of approximately 4%, pan-
creatic ductal adenocarcinoma is one of the most aggressive
human malignancies. Studies that aimed at the understanding
of this exceptionally aggressive behavior discovered an increas-
ing number of genetic and epigenetic alterations such as dereg-
ulated growth factor receptor/ligand systems, oncogenes, tumor
suppressors, metastasis suppressors and related signal trans-
duction pathways. Alterations of these genes and their respec-
tive proteins may occur throughout pancreatic carcinogenesis
suggesting an adenoma-carcinoma model with an increasing
number of molecular and cellular alterations. The most com-
monly mutated oncogene in pancreatic cancer is K-ras which
induces cell proliferation via MAPK signaling. On the other
hand, mutations in tumor suppressors such as p53, p16 and
Smad4 also occur frequently. Besides, there are less common
mutations in the tumor suppressor genes STK11, APC, FHIT,
DCC, ARP, BRCA2, MKK4, TbR-I and TbR-II. Epigenetic alterations
in growth promoting signaling pathways of the EGF, IGF and FGF
family as well as autocrine or paracrine effects of their respec-
tive ligands have been shown to endow a growth advantage to
pancreatic cancer cells. Concomitantly, it was shown that the
important growth inhibitory pathway mediated by TGF-beta
family members and their intracellular signal transduction mol-
ecules is lost in pancreatic cancer. Resistance to apoptotic cell
death gives cancer cells a further growth advantage with down-
regulation of pro-apoptotic factors such as bak and bcl-2 or
upregulation of anti-apoptotic bcl-XL. Furthermore, aberrant
expression of genes influencing invasion and metastasis is
observed. Among those, heparanase, matrix metalloproteinases
and galectins have been shown to mainly influence invasion
while decreased expression of the metastasis suppressor KAI1
was associated with worse survival and an increased metastatic
potential.
Identified alterations of signal transduction pathways can be
used clinically as therapeutic targets, e.g. small-molecule tyrosine
kinase inhibitors and other approaches show encouraging results
in first clinical trials.
Thus, a translational research approach will be a promising
way to slow down tumor progression and improve survival and
quality of life of pancreatic cancer patients in the future.
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In breast cancer, tumor biological markers are urgently needed
to individualize clinical decision making, particularly in order
to avoid overtreatment in the increasing number of patients
with small tumors. Urokinase-type plasminogen activator uPA
and its inhibitor PAI-1 are the first novel markers validated at
the highest level of evidence for their prognostic and predictive
impact by a multicenter therapy trial (Chemo N0) and a large
EORTC-RBG pooled analysis. Their greatest clinical use so far is
in node-negative (N0) breast cancer where the test can be used
to avoid adjuvant chemotherapy in patients with non-aggressive
disease. In addition, in intermediate-risk patients as defined by
the St. Gallen consensus, the test can be used to identify
patients who should receive chemotherapy because their tumor
has a more aggressive biology than classical pathological factors
would otherwise lead to believe. The NNBC3 therapy trial (AGO,
GBG, and EORTC PBG), which has already recruited almost 700
patients, compares risk assessment by uPA/PAI-1 to that by
established prognostic factors and evaluates optimization of
chemotherapy (FEC vs. FEC-DOC) in high-risk N0 patients. Other
promising markers include methylation markers such as PITX2
for identification of patients with good outcome under adjuvant
endocrine therapy, microarray signatures or multi-gene scores
for risk group stratification. In addition to NNBC3, other large
international therapy trials in N0 breast cancer using gene signa-
tures for risk group stratification will soon start recruitment.
The current and future challenge is to integrate the most prom-
ising tumor biological factors into advanced decision support
algorithms.
doi:10.1016/j.ejcsup.2006.04.023
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Intrinsic or acquired resistance to chemotherapy is responsible
for failure of current treatment regimens in breast cancer. For
instance, transcription factor YB-1 regulates expression of P-gly-
coprotein gene mdr1 which plays a major role in the development
of a multidrug-resistant tumor phenotype. High YB-1 protein
expression in tumor tissue and surrounding benign epithelial
cells is significantly associated with poor outcome in patients
who received postoperative chemotherapy, indicating clinical
drug resistance. Furthermore, in untreated patients, those with
low YB-1 protein expression are still free of disease, whereas
the 5-year relapse rate in those with elevated YB-1 is 30%.
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